Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 16.95 is 21% above its 5-year average of 14.01, around the middle of its 5-year range (6.86–23.99).
As of the fiscal period ended Tuesday, June 30, 2026. 26.42% above its 12-month average of 13.41.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 16.95.
CURRENT RATIO
16.95
CURRENT RATIO AVG TTM
13.41
CURRENT RATIO AVG 3Y
15.74
CURRENT RATIO AVG 5Y
14.01
CURRENT RATIO AVG 10Y
11.21
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+26.42%
CURRENT VS 3Y AVG
+7.70%
CURRENT VS 5Y AVG
+20.94%
CURRENT VS 10Y AVG
+51.18%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+351.98%
vs the sector median at left
Viridian Therapeutics, Inc.
Market Cap
$2.06B
Current Ratio
16.95
TTM Avg
13.41
3Y Avg
15.74
5Y Avg
14.01
Market Cap
$2.06B
Current Ratio
11.82
TTM Avg
14.70
3Y Avg
15.08
5Y Avg
16.52
Market Cap
$2.02B
Current Ratio
2.32
TTM Avg
2.34
3Y Avg
3.23
5Y Avg
3.57
Market Cap
$2.11B
Current Ratio
18.83
TTM Avg
6.22
3Y Avg
3.45
5Y Avg
3.57
Market Cap
$2.02B
Current Ratio
5.42
TTM Avg
4.91
3Y Avg
6.23
5Y Avg
8.44
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | $2.06B | 16.95 | 13.41 | 15.74 | 14.01 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | 11.82 | 14.70 | 15.08 | 16.52 |
| Alvotech (ALVO)vs › | $2.08B | 1.65 | 2.12 | 1.59 | 1.52 |
| Vericel Corporation (VCEL)vs › | $2.05B | 5.04 | 4.63 | 4.69 | 5.05 |
| Progyny, Inc. (PGNY)vs › | $2.03B | 2.14 | 2.76 | 2.92 | 2.79 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | 2.32 | 2.34 | 3.23 | 3.57 |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | 18.83 | 6.22 | 3.45 | 3.57 |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | 3.80 | 5.01 | 5.21 | 5.22 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 5.42 | 4.91 | 6.23 | 8.44 |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | 10.92 | 19.66 | 12.98 | 14.20 |
Current Ratio
16.95
Quick Ratio
16.95
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 16.95 |
| 2026-03-31 | 15.15 |
| 2025-12-31 | 12.65 |
| 2025-09-30 | 11.28 |
| 2025-06-30 | 11.01 |
| 2025-03-31 | 19.49 |
| 2024-12-31 | 15.43 |
| 2024-09-30 | 18.55 |
| 2024-06-30 | 15.82 |
| 2024-03-31 | 23.99 |
| 2023-12-31 | 18.26 |
| 2023-09-30 | 13.93 |
| 2023-06-30 | 12.09 |
| 2023-03-31 | 12.64 |
| 2022-12-31 | 12.73 |
| 2022-09-30 | 17.35 |
| 2022-06-30 | 7.77 |
| 2022-03-31 | 12.47 |
| 2021-12-31 | 14.68 |
| 2021-09-30 | 15.20 |
| 2021-06-30 | 6.86 |
| 2021-03-31 | 7.39 |
| 2020-12-31 | 12.14 |
| 2020-09-30 | 4.23 |
| 2020-06-30 | 4.84 |
| 2020-03-31 | 4.43 |
| 2019-12-31 | 2.92 |
| 2019-09-30 | 3.68 |
| 2019-06-30 | 5.26 |
| 2019-03-31 | 7.90 |
| 2018-12-31 | 9.71 |
| 2018-09-30 | 11.09 |
| 2018-06-30 | 18.96 |
| 2018-03-31 | 20.87 |
| 2017-12-31 | 13.31 |
| 2017-09-30 | 7.10 |
| 2017-06-30 | 7.44 |
| 2017-03-31 | 7.82 |
| 2016-12-31 | 0.93 |
| 2016-09-30 | 2.28 |
| 2016-06-30 | 3.07 |
| 2016-03-31 | 3.96 |
| 2015-12-31 | 4.75 |
| 2015-09-30 | 6.44 |
| 2015-06-30 | 5.72 |
| 2015-03-31 | 5.81 |
| 2014-12-31 | 3.41 |
| 2014-09-30 | 4.34 |
| 2014-06-30 | 4.57 |
| 2014-03-31 | 0.93 |
| 2013-12-31 | 1.48 |
| 2013-09-30 | 0.00 |
| 2013-06-30 | 0.00 |
| 2013-03-31 | 0.00 |
